Search results
Showing 256 to 270 of 704 results for end of life care
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.